Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Abbott Laboratories's Ending Cash Position for the quarter that ended in Jun. 2026 was MXN89,060 Mil.
Abbott Laboratories's quarterly Ending Cash Position
declined
from Dec. 2025 (MXN153,445 Mil) to Mar. 2026 (MXN122,676 Mil) and
declined
from Mar. 2026 (MXN122,676 Mil) to Jun. 2026 (MXN89,060 Mil).
Abbott Laboratories's annual Ending Cash Position
increased
from Dec. 2023 (MXN117,054 Mil) to Dec. 2024 (MXN158,837 Mil) but then
declined
from Dec. 2024 (MXN158,837 Mil) to Dec. 2025 (MXN153,445 Mil).
Abbott Laboratories Ending Cash Position Related Terms
Abbott Laboratories Ending Cash Position Historical Data
* Premium members only.
The historical data trend for Abbott Laboratories's Ending Cash Position can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abbott Laboratories Ending Cash Position Calculation
Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.
Abbott Laboratories's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as
What does a Ending Cash Position of MXN89,060 Mil mean?
Abbott Laboratories (MEX:ABT) has a Ending Cash Position of MXN89,060 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Abbott Laboratories and its competitors.
Is Abbott Laboratories' Ending Cash Position too high?
Abbott Laboratories' current Ending Cash Position is MXN89,060 Mil. Overall, Abbott Laboratories has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abbott Laboratories' Ending Cash Position compare to SYK and MDT?
Abbott Laboratories' Ending Cash Position of MXN89,060 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Devices & Instruments company?
A good Ending Cash Position depends on the Medical Devices & Instruments industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Abbott Laboratories and its competitors. Abbott Laboratories's current Ending Cash Position is MXN89,060 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbott Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Abbott Laboratories (MEX:ABT) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN2,274.82, compared to a current price of MXN1,870.00 — trading 17.8% below its estimated fair value. The current Ending Cash Position is MXN89,060 Mil. Abbott Laboratories' overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Abbott Laboratories (MEX:ABT), the current Ending Cash Position is MXN89,060 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abbott Laboratories (MEX:ABT) Overvalued in 2026?
Based on GuruFocus' analysis, Abbott Laboratories stock appears to be undervalued.
The current stock price of MXN1,870.00 is trading 17.8% below its estimated GF Value™ of MXN2,274.82.
GuruFocus considers Abbott Laboratories to be Modestly Undervalued.
Key valuation signals for MEX:ABT:
Ending Cash Position: MXN89,060 Mil
GF Value™: MXN2,274.82 vs. price of MXN1,870.00 (17.8% below fair value)
No single metric tells the full story. See the MEX:ABT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
81GF Score
Get the complete analysis for MEX:ABT
Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ABT has been successfully added to your 
